Samin Houshyar, MD

Wilmot Cancer Institute, University of Rochester Medical Center

Poster(s):

• 1803 - Real-world Treatment Outcomes among Patients with High-Risk CLL/SLL Receiving Venetoclax-Based Therapy in 1L or 2L: An Updated International Study